Quick Answer
Kairos Pharma, LTD. reported Cash and Equivalents of $4.49 million for fiscal year 2025.
Kairos Pharma, LTD. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $4.49M | +253.1% |
| 2024 | $1.27M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $5.58M | — | +83.8% |
| June 30, 2025 | $3.03M | — | -16.1% |
| March 31, 2025 | $3.62M | — | +184.3% |
| December 31, 2024 | $1.27M | — | — |
- Kairos Pharma, LTD. showed an increase of +253.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2024–2025 period, Kairos Pharma, LTD.’s cash and equivalents has grown by 253.1% (from $1.27 million to $4.49 million).
- The most recent figure is from Kairos Pharma, LTD.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: